Bilateral endobronchial valves treatment for severe emphysema.

Autor:	Guibert N; Pulmonology Dept, Larrey University Hospital, Toulouse, France.; Paul Sabatier Toulouse University III, Toulouse, France., Fumat R; Pulmonology Dept, Larrey University Hospital, Toulouse, France., Dupuis M; Pulmonology Dept, Larrey University Hospital, Toulouse, France., Dusselier M; Pulmonology Dept, Dupuytren University Hospital, Limoges, France., Favard F; Pulmonology Dept, Dupuytren University Hospital, Limoges, France., Heluain V; Pulmonology Dept, Larrey University Hospital, Toulouse, France., Mallah S; Pulmonology Dept, Larrey University Hospital, Toulouse, France., Barthes R; Pulmonology Dept, Larrey University Hospital, Toulouse, France., Simonneau Y; Pulmonology Dept, Dupuytren University Hospital, Limoges, France., Egenod T; Pulmonology Dept, Dupuytren University Hospital, Limoges, France.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2022 Apr 11; Vol. 8 (2). Date of Electronic Publication: 2022 Apr 11 (Print Publication: 2022).
DOI:	10.1183/23120541.00672-2021
Abstrakt:	Bilateral endobronchial valves treatment can lead to additional significant benefits in patients who respond to the first procedure and have a clear target lobe on both lungs but increases the rate of complications https://bit.ly/3J0mZ8h. Competing Interests: Conflict of interest: N. Guibert reports receiving personal fees for participation on a data safety monitoring board or advisory board for PulmonX, outside the submitted work. Conflict of interest: R. Fumat has nothing to disclose. Conflict of interest: M. Dupuis has nothing to disclose. Conflict of interest: M. Dusselier has nothing to disclose. Conflict of interest: F. Favard has nothing to disclose. Conflict of interest: V. Heluain has nothing to disclose. Conflict of interest: S. Mallah has nothing to disclose. Conflict of interest: R. Barthes has nothing to disclose. Conflict of interest: Y. Simonneau has nothing to disclose. Conflict of interest: T. Egenod reports receiving personal fees for participation on a data safety monitoring board or advisory board for PulmonX, outside the submitted work. (Copyright ©The authors 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu